Kymera Therapeutics, Inc. · NASDAQ:KYMR
Mainolfi Nello sold 30,000 Kymera Therapeutics, Inc. shares (Form 4)
Traded Apr 29, 2026 · Filed Apr 29, 2026
On Apr 29, 2026, Mainolfi Nello (Director, Chief Executive Officer) sold 30,000 Kymera Therapeutics, Inc. shares at an average US$81.18 for US$2.44M under a trading plan, leaving 666,195 shares. Filed Apr 29, 2026 (Form 4).
- Sold
- 30,000 shares
- Price
- US$81.18 average (US$80.74 to US$82.45)
- Value
- US$2.44M
- Holding after
- 666,195 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, Chief Executive Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Common Stock | Option exercise | 30,000 | US$2.08 | 696,195 | Direct |
| Apr 29, 2026 | Common Stock | Sale | 17,005 | US$80.74 | 679,190 | Direct |
| Apr 29, 2026 | Common Stock | Sale | 12,059 | US$81.70 | 667,131 | Direct |
| Apr 29, 2026 | Common Stock | Sale | 936 | US$82.45 | 666,195 | Direct |
Source
Related
- Kymera Therapeutics, Inc.
- Mainolfi Nello
- Kymera Therapeutics, Inc. shareholders
- Form 4 · Mainolfi Nello · Oct 1, 2026
- Form 4 · Mainolfi Nello · Jul 7, 2026
- Form 4 · Mainolfi Nello · Jul 2, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Sep 8, 2026
- Form 4 · Adams Brian · Sep 4, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Atlas Venture Fund X, L.P. · Aug 13, 2026
- Form 4 · Rooney Terence · Jul 27, 2026